We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.71% | 1,773.50 | 1,772.00 | 1,772.50 | 1,776.00 | 1,766.00 | 1,770.00 | 6,684,113 | 16:35:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.81 | 72.97B |
From May 2019 to May 2024
NEW YORK (Agefi-Dow Jones)--GlaxoSmithKline a annoncé mardi que la Food & Drug Administration (FDA), l'autorité sanitaire américaine, avait accordé une évaluation prioritaire à sa demande de licence de produit biologique pour le belantamab mafodotin, un médicament contre le myélome multiple.
Le groupe pharmaceutique britannique a indiqué que cette demande concernait le traitement de patients atteints de myélome multiple récidivant ou réfractaire ayant déjà suivi une thérapie comprenant un agent immunomodulateur, un inhibiteur du protéasome et un anticorps anti-CD38.
La FDA accorde une évaluation prioritaire aux médicaments pouvant potentiellement améliorer de manière importante le traitement d'une maladie grave.
-Colin Kellaher, Dow Jones Newswires
(Version française Lydie Boucher) ed : FXS
Agefi-Dow Jones The financial newswire
(END) Dow Jones Newswires
January 21, 2020 11:52 ET (16:52 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
